keyword
MENU ▼
Read by QxMD icon Read
search

ADV experienced

keyword
https://www.readbyqxmd.com/read/28913988/prevalence-of-respiratory-viral-infections-in-korean-adult-asthmatics-with-acute-exacerbations-comparison-with-those-with-stable-state
#1
Ki Hyun Seo, Da Jeong Bae, Ji Na Kim, Ho Sung Lee, Yong Hoon Kim, Jong Sook Park, Myung Shin Kim, Hun Soo Chang, Ji Hye Son, Dong Gyu Baek, Jun Suk Lee, Choon Sik Park
PURPOSE: Viral infections are involved in ~50% of exacerbations among Caucasian adult asthmatics. However, there have been few reports on the causative virus of exacerbations in Korean adult asthmatics. Thus, we compared frequencies and types of viruses between lower respiratory tract illnesses (LRTIs) with exacerbations (exacerbated LRTIs) and those without exacerbations (stable LRTIs) to evaluate contribution of respiratory viruses to exacerbations. METHODS: Viral RNA was extracted from sputum using the Viral Gene-spin™ Kit...
November 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/28899646/early-life-adversity-potentiates-expression-of-addiction-related-traits
#2
Tristan J Hynes, Catherine S Thomas, Alicia S Zumbusch, Anna Samson, Ioana Petriman, Una Mrdja, Angelique Orr, Emilie Cutts, Bruce G Ruzindana, Alimohamed Hazari, Margaret Zjadewicz, Vedran Lovic
Many individuals sporadically and circumstantially sample addictive drugs, yet few become addicted. The individual vulnerabilities underlying the development of addiction are not well understood. Correlational findings show that early life adversity is associated with a greater propensity to develop drug addiction. However, the mechanisms by which early life adversity increases addiction vulnerability are unknown. Separate lines of research have found that several traits are associated with addiction. Here, we examined the effects of early life adversity on addiction-related traits in adulthood...
September 9, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28870666/tenofovir-alafenamide-as-a-rescue-therapy-in-a-patient-with-hbv-cirrhosis-with-a-history-of-fanconi-syndrome-and-multidrug-resistance
#3
Glenda Grossi, Alessandro Loglio, Floriana Facchetti, Marta Borghi, Roberta Soffredini, Enrico Galmozzi, Giovanna Lunghi, Anuj Gaggar, Pietro Lampertico
Tenofovir disoproxil fumarate (TDF) is a recommended first-line therapy for both naïve and experienced patients with chronic hepatitis B (CHB), although reduced estimated glomerular filtration rate (eGFR), hypophosphatemia, hyperphosphaturia and Fanconi syndrome have been reported in some patients. Entecavir (ETV) could be considered as a rescue therapy for TDF-treated patients developing renal dysfunction, though patients with prior history of treatment with lamivudine (LAM) can develop ETV resistance strains, which can lead to potentially severe hepatitis flares...
September 21, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28783452/off-the-shelf-virus-specific-t-cells-to-treat-bk-virus-human-herpesvirus-6-cytomegalovirus-epstein-barr-virus-and-adenovirus-infections-after-allogeneic-hematopoietic-stem-cell-transplantation
#4
Ifigeneia Tzannou, Anastasia Papadopoulou, Swati Naik, Kathryn Leung, Caridad A Martinez, Carlos A Ramos, George Carrum, Ghadir Sasa, Premal Lulla, Ayumi Watanabe, Manik Kuvalekar, Adrian P Gee, Meng-Fen Wu, Hao Liu, Bambi J Grilley, Robert A Krance, Stephen Gottschalk, Malcolm K Brenner, Cliona M Rooney, Helen E Heslop, Ann M Leen, Bilal Omer
Purpose Improvement of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will require efforts to decrease treatment-related mortality from severe viral infections. Adoptively transferred virus-specific T cells (VSTs) generated from eligible, third-party donors could provide broad antiviral protection to recipients of HSCT as an immediately available off-the-shelf product. Patient and Methods We generated a bank of VSTs that recognized five common viral pathogens: Epstein-Barr virus (EBV), adenovirus (AdV), cytomegalovirus (CMV), BK virus (BKV), and human herpesvirus 6 (HHV-6)...
November 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28668490/co-infections-by-double-stranded-dna-viruses-after-ex-vivo-t-cell-depleted-cd34-selected-hematopoietic-cell-transplantation
#5
Yao-Ting Huang, Seong Jin Kim, Yeon Joo Lee, Daniel Burack, Paige Nichols, Molly Maloy, Miguel-Angel Perales, Sergio A Giralt, Ann A Jakubowski, Genovefa A Papanicolaou
Recipients of ex vivo T cell-depleted (TCD) hematopoietic cell transplantation (HCT) are at risk of infection by double-stranded (ds) DNA viruses. We report rates of dsDNA viremia, end-organ disease (EOD), infection-related mortality, and overall survival (OS) in a contemporary cohort of adult TCD HCT recipients routinely monitored for cytomegalovirus (CMV), adenovirus (ADV), human herpesvirus 6 (HHV6), and Epstein-Barr virus (EBV). Healthcare utilization in the first 6 months post-HCT was compared between patients with dsDNA viremia versus no viremia...
October 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28511283/a-different-inhibitor-is-required-for-overcoming-entecavir-resistance-a-comparison-of-four-rescue-therapies-in-a-retrospective-study
#6
Guosheng Yuan, Chengguang Hu, Yuchen Zhou, Junwei Liu, Huaping Huang, Yuan Li, Dinghua Yang, Fuyuan Zhou, Yong-Yuan Zhang, Yuanping Zhou
AIMS: Little clinical data are available regarding re-establishing the effective inhibition of entecavir (ETV)-resistant mutants. In this retrospective study, we aimed to compare the efficacies of four treatment regimens as rescue therapy for those chronic hepatitis B (CHB) patients with ETV resistance. METHODS: A total of 65 patients with ETV resistance were assigned either with tenofovir disoproxil fumarate (TDF) monotherapy (n = 21), ETV (0.5 mg) plus adefovir (ADV) combination therapy (n = 19), ETV (1...
October 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28179096/long-term-efficacy-and-safety-of-switching-from-lamivudine-adefovir-to-tenofovir-disoproxil-fumarate-in-virologically-suppressed-patients
#7
Massimo Fasano, Paolo Maggi, Armando Leone, Anna Volpe, Jose Ramon Fiore, Gioacchino Angarano, Teresa Antonia Santantonio
BACKGROUND AND AIM: Tenofovir disoproxil fumarate (TDF) is recommended as first-line monotherapy for nucleos(t)ide (NA)-naïve chronic hepatitis B (CHB) patients and as a second-line rescue therapy for NA-experienced patients with a previous treatment failure. However, data regarding the efficacy of TDF monotherapy in patients with lamivudine resistance (LAM-R) successfully treated with LAM+adefovir (ADV) are limited. Herein, the efficacy and safety of switching from LAM+ADV to TDF monotherapy in clinical practice have been evaluated...
January 16, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28114428/treatment-efficacy-and-safety-of-tenofovir-based-therapy-in-chronic-hepatitis-b-a-real-life-cohort-study-in-korea
#8
Hyo Jun Ahn, Myeong Jun Song, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
BACKGROUND & AIMS: We evaluated the efficacy and safety of Tenofovir disoproxil fumarate (TDF)-based therapy in naïve and treatment-experienced chronic hepatitis B (CHB) patients for 96 weeks in Korean real life practice. METHODS: A total of 209 CHB patients with a prescription for TDF at the Seoul and Daejeon St. Mary's hospitals were enrolled from December 2012 to October 2014. We compared the virological responses and evaluated the renal safety of treatment-naive and treatment-experienced patients...
2017: PloS One
https://www.readbyqxmd.com/read/27896895/five-year-efficacy-and-safety-of-tenofovir-based-salvage-therapy-for-patients-with-chronic-hepatitis-b-who-previously-failed-lam-adv-therapy
#9
Lucy Lim, Alexander Thompson, Scott Patterson, Jacob George, Simone Strasser, Alice Lee, William Sievert, Amanda Nicoll, Paul Desmond, Stuart Roberts, Kaye Marion, Scott Bowden, Stephen Locarnini, Peter Angus
BACKGROUND: Multidrug-resistant HBV continues to be an important clinical problem. The TDF-109 study demonstrated that TDF±LAM is an effective salvage therapy through 96 weeks for LAM-resistant patients who previously failed ADV add-on or switch therapy. We evaluated the 5-year efficacy and safety outcomes in patients receiving long-term TDF±LAM in the TDF-109 study. METHODS: A total of 59 patients completed the first phase of the TDF-109 study and 54/59 were rolled over into a long-term prospective open-label study of TDF±LAM 300 mg daily...
June 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27602500/pre-existing-mutations-related-to-tenofovir-in-chronic-hepatitis-b-patients-with-long-term-nucleos-t-ide-analogue-drugs-treatment-by-ultra-deep-pyrosequencing
#10
Xiaxia Zhang, Minran Li, Hongli Xi, Renwen Zhang, Jianhong Chen, Yu Zhang, Xiaoyuan Xu
AIMS: The dynamics of resistance-associated mutations under combination therapy were explored. METHODS: A total of 46 patients were classified into adefovir (n=14) and entecavir (n=32) groups. In the adefovir (ADV) group, six patients receiving combined therapy were DNA-positive after more than 3 years of therapy. Ultra-deep pyrosequencing was used to analyze the dynamics of multi-drugs resistance mutations. RESULTS: At baseline, all 46 treatment-naïve patients harbored rtA181V/T substitutions (1...
October 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27482652/brincidofovir-clearance-of-acyclovir-resistant-herpes-simplex-virus-1-and-adenovirus-infection-after-stem-cell-transplantation
#11
S Voigt, J Hofmann, A Edelmann, A Sauerbrei, J-S Kühl
Infections with adenovirus (AdV) and herpesviruses can result in considerable morbidity and mortality in pediatric hematopoietic stem cell transplant (SCT) recipients. Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections. We report a child with myelodysplastic syndrome undergoing multiple SCT, who experienced HSV-1 disease including severe mucositis and herpetic whitlow, as well as high viral load AdV DNAemia...
October 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27364728/a-five-years-study-of-antiviral-effect-of-entecavir-in-chinese-chronic-hepatitis-b-patients
#12
Kehui Liu, Xiaogang Xiang, Rebecca Bao, Rong Chen, Yunye Liu, Jingdong Xie, Qing Guo, Shisan Bao, Qing Xie, Hui Wang
Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients. To investigate the efficacy of ETV in Chinese nucleos(t)ide(NA)-experienced CHB patients. Among 89 CHB patients with ETV monotherapy for ≥6 months, 33/89 (37%) or 56/89 (73%) were NA-naïve or NA-experienced. During a median follow-up of 5.75 years, all NA-naïve CHB patients achieved VR without genotypic ETV-resistance. However, VR was observed in 50/56 (~90%) of NA-experienced CHB patients during a median follow-up of 4...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27357598/durability-of-the-virological-response-after-lamivudine-discontinuation-in-lamivudine-resistant-patients-with-a-complete-virological-response-after-lamivudine-and-adefovir-combination-therapy
#13
Mi Na Kim, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Kwang-Hyub Han
We investigated the durability of virological response after lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CHB) patients with complete virological response after LAM-adefovir (ADV) combination therapy. We enrolled 58 patients switched to ADV monotherapy with undetectable viral loads (<12 IU/ml) and normal alanine aminotransferase levels after ADV add-on combination treatment for at least 6 months in LAM-resistant CHB patients. Virologic relapse was defined as HBV DNA detection at more than 20 IU/ml by quantitative polymerase chain reaction determined on two consecutive measurements...
January 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/27206517/entecavir-plus-tenofovir-combination-therapy-for-chronic-hepatitis-b-in-patients-with-previous-nucleos-t-ide-treatment-failure
#14
MULTICENTER STUDY
Fabien Zoulim, Jolanta Białkowska-Warzecha, Mircea Mihai Diculescu, Adrian Eugen Goldis, Renate Heyne, Tomasz Mach, Patrick Marcellin, Jörg Petersen, Krzysztof Simon, Soumaya Bendahmane, Isabelle Klauck, Wojciech Wasiak, Harry L A Janssen
BACKGROUND AND AIMS: In patients with chronic hepatitis B (CHB) who have failed on other nucleos(t)ide analogs (NUCs), the combination of entecavir (ETV) plus tenofovir disoproxil fumarate (TDF), two potent agents with non-overlapping resistance profiles, may provide a single rescue regimen. METHODS: In this single-arm, open-label study, 92 CHB patients with a primary non-response, partial response, or virologic breakthrough on their current NUC were switched to ETV (1 mg) plus TDF (300 mg) and treated for 96 weeks...
September 2016: Hepatology International
https://www.readbyqxmd.com/read/27016894/profile-of-hbv-polymerase-gene-mutations-during-entecavir-treatment-in-patients-with-chronic-hepatitis-b
#15
Mei Sun, Guolei Tan, Jinyun Song, Jianfang Wang, Xuping Wu
BACKGROUND/AIMS: We investigated the efficacy of entecavir (ETV) monotherapy in 54 naïve patients and 27 lamivudine (LMV) and/or adefovir (ADV) experienced patients. METHODS: Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0.5mg daily. The viruses of patients were sequenced before ETV therapy and after every three months of ETV therapy. RESULTS: Eight LAM-experienced and ADV-experienced patients emerged mutations in the ETV treatment...
November 2016: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/25923228/entecavir-combined-with-adefovir-ameliorates-patients-with-chronic-hepatitis-b-who-fail-to-respond-to-nucleotide-acid-analog-monotherapy
#16
Xiang-Yong Li, Xu You, Yu-Sheng Jie, Guo-Li Lin, Yuan-Kai Wu, Ming-Xing Huang, Min Zhang, Zhan-Yi Li, Dong-Ying Xie, Zhi-Liang Gao, Yu-Tian Chong
The aim of this study was to evaluate the efficacy and safety of entecavir (ETV) combined treatment with adefovir (ADV) on chronic hepatitic B (CHB) patients who failed to respond to nucleotide (acid) analog (NA) treatment. On this basis, the possible factors in the combined treatment of these patients will be analyzed. The safety, biochemical index, and the possible factors that might affect the ETV and ADV combined treatment at different points in time were retrospectively analyzed. The biochemical index included the following: virological response, hepatitis B virus (HBV) DNA decline, primary nonresponse, biochemical response, and the hepatitis B virus E antigen/hepatitis B virus E antibody seroconversion rate...
May 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/25742145/clinical-course-of-chronic-hepatitis-b-patients-receiving-nucleos-t-ide-analogues-after-virological-breakthrough-during-monotherapy-with-lamivudine
#17
Maria Antonia De Francesco, Franco Gargiulo, Angiola Spinetti, Serena Zaltron, Cinzia Giagulli, Francesca Caccuri, Francesco Castelli, Arnaldo Caruso
Little is known about the optimal management of patients with chronic hepatitis B (CHB) who develop drug resistance. The aim of this study was to investigate the effectiveness of different drug regimens in chronically HBV-infected patients. HBV viral load was determined using a bDNA assay and the substitutions in HBV-DNA were studied by polymerase sequencing test. The study involved 38 patients who experienced a therapeutic failure to lamivudine (LAM). The sequential treatments used were: LAM + adefovir (ADV), LAM + tenofovir (TDF), entecavir (ETV) monotherapy, ADV monotherapy and TDF monotherapy...
January 2015: New Microbiologica
https://www.readbyqxmd.com/read/25671826/lam-add-on-adv-combination-therapy-or-etv-monotherapy-for-chb-patients-with-suboptimal-response-to-adv
#18
RANDOMIZED CONTROLLED TRIAL
Hongyu Jia, Feng Ding, Jianyang Chen, Yimin Zhang, Dairong Xiang, Jiangshan Lian, Linyan Zeng, Liang Yu, Jianhua Hu, Yongtao Li, Yingfeng Lu, Yuanchun Liu, Lin Zheng, Lanjuan Li, Yida Yang
INTRODUCTION: Among the available nucleos(t)ide analogues adefovir dipivoxil (ADV) is relatively cheap and widely used in rural area in China. However, there are insufficient data on recommendation for patients with suboptimal response to ADV after 48 weeks of treatment in order to reduce the resistance rate in the long term. The aim of this study was to compare the efficacy and safety of LAM add-on combination therapy versus ETV monotherapy for patients with suboptimal response to ADV...
March 2015: Annals of Hepatology
https://www.readbyqxmd.com/read/25395224/dating-violence-and-substance-use-exploring-the-context-of-adolescent-relationships
#19
Charlene K Baker
The connection between adolescent dating violence (ADV) and substance use is important to consider because of the serious consequences for teens who engage in these behaviors. Although prior research shows that these two health problems are related, the context in which they occur is missing, including when (i.e., the timeline) in the relationship these events occur. To fill this gap, eight sex-specific focus groups were conducted with 39 high school-aged teens, all of whom had experienced prior relationship violence...
March 2016: Journal of Interpersonal Violence
https://www.readbyqxmd.com/read/25168842/safety-and-efficacy-of-entecavir-in-adefovir-experienced-patients
#20
Nghia H Nguyen, Huy N Trinh, Thuan T Nguyen, Son T Do, Phuong Tran, Huy A Nguyen, Khanh K Nguyen, Ruel T Garcia, Glen A Lutchman, Mindie H Nguyen
BACKGROUND AND AIM: Suboptimal viral suppression with adefovir (ADV) poses a challenge in managing chronic hepatitis B. Few studies have evaluated the efficacy of entecavir (ETV) in ADV-experienced patients. Our aim is to assess treatment effectiveness of ETV in ADV-experienced patients. METHODS: ADV-experienced patients switched to ETV were enrolled from six US clinics. Patients completed a median of 24 months of ETV after switch. Patients were categorized into partial responders (detectable HBV-DNA at switch) or complete responders (undetectable HBV-DNA at switch) to ADV...
January 2015: Journal of Gastroenterology and Hepatology
keyword
keyword
3093
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"